JP2009510165A - 低酸素細胞を選択的に枯渇させるための方法 - Google Patents

低酸素細胞を選択的に枯渇させるための方法 Download PDF

Info

Publication number
JP2009510165A
JP2009510165A JP2008534614A JP2008534614A JP2009510165A JP 2009510165 A JP2009510165 A JP 2009510165A JP 2008534614 A JP2008534614 A JP 2008534614A JP 2008534614 A JP2008534614 A JP 2008534614A JP 2009510165 A JP2009510165 A JP 2009510165A
Authority
JP
Japan
Prior art keywords
cells
bone marrow
subject
agent
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008534614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510165A5 (cg-RX-API-DMAC7.html
Inventor
カリンディ パマー，
ピーター マウフ，
ジュリアン ダウン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Genetix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetix Pharmaceuticals Inc filed Critical Genetix Pharmaceuticals Inc
Publication of JP2009510165A publication Critical patent/JP2009510165A/ja
Publication of JP2009510165A5 publication Critical patent/JP2009510165A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008534614A 2005-10-03 2006-09-29 低酸素細胞を選択的に枯渇させるための方法 Pending JP2009510165A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72318305P 2005-10-03 2005-10-03
PCT/US2006/038553 WO2007041546A2 (en) 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells

Publications (2)

Publication Number Publication Date
JP2009510165A true JP2009510165A (ja) 2009-03-12
JP2009510165A5 JP2009510165A5 (cg-RX-API-DMAC7.html) 2009-11-05

Family

ID=37826084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534614A Pending JP2009510165A (ja) 2005-10-03 2006-09-29 低酸素細胞を選択的に枯渇させるための方法

Country Status (5)

Country Link
US (1) US20090136521A1 (cg-RX-API-DMAC7.html)
EP (1) EP1931769A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009510165A (cg-RX-API-DMAC7.html)
CA (1) CA2624707A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007041546A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
WO2008033039A1 (en) * 2006-09-11 2008-03-20 Adam Vorn Patterson Cancer treatment
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
CA2706378C (en) 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法
ES2884674T3 (es) * 2008-10-21 2021-12-10 Immunogenesis Inc Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed
WO2010132771A1 (en) 2009-05-15 2010-11-18 Lankenau Institute For Medical Research Methods and kits for measuring toxicity and oxidative stress in live cells
US8269197B2 (en) 2009-07-22 2012-09-18 Intraop Medical Corporation Method and system for electron beam applications
CN102933258A (zh) 2010-03-01 2013-02-13 因特奥普医药公司 与含氧量低的细胞敏化剂联用的放疗
MX2012014428A (es) 2010-07-12 2013-03-05 Threshold Pharmaceuticals Inc Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
JP2015500885A (ja) 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2015013448A1 (en) 2013-07-26 2015-01-29 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794742A (fr) * 1972-02-01 1973-07-30 Bayer Ag Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition
US3957779A (en) * 1972-11-15 1976-05-18 Bayer Aktiengesellschaft Benzo-1,2,4-triazines
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
DK1014990T3 (da) * 1997-03-07 2006-12-11 Sanofi Aventis Us Llc Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN5008015774; ＤＡＮＥＴ　ＧＵＥＮＡＨＥＬ　Ｈ: ＴＨＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＬＩＮＩＣＡＬ　ＩＮＶＥＳＴＩＧＡＴＩＯＮ Ｖ１１２　Ｎ１, 200307, Ｐ１２６-１３５ *
JPN5008015775; ＤＯＷＮ　ＪＵＬＩＡＮ　Ｄ: ＢＬＯＯＤ Ｖ１０４　Ｎ１１　ＰＡＲＴ　１, 20041116, Ｐ１９２Ａ *
JPN5008015776; ＤＡＮＥＴ　ＧＵＥＮＡＨＥＬ　Ｈ: ＢＬＯＯＤ Ｖ１００　Ｎ１１, 20021116, Ｐ２９３Ａ *
JPN5008015777; ＷＥＳＴＥＲＨＯＦ　Ｇ　Ｒ: ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ６０　Ｎ１９, 20001001, Ｐ５４７０-５４７８, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ *
JPN5008015778; ＤＯＷＮ　Ｊ　Ｄ: ＢＲＩＴＩＳＨ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ Ｖ７０　Ｎ４, 1994, Ｐ６１１-６１６ *
JPN5008015779; ＤＯＷＮ　Ｊ　Ｄ: ＥＸＰＥＲＩＭＥＮＴＡＬ　ＨＥＭＡＴＯＬＯＧＹ Ｖ２１　Ｎ７, 199307, Ｐ９１３-９２１ *
JPN6012022982; ＢＲＯＷＮ，Ｊ．Ｍ．　ｅｔ　ａｌ: 'Ｅｘｐｌｏｉｔｉｎｇ　ｔｕｍｏｕｒ　ｈｙｐｏｘｉａ　ｉｎ　ｃａｎｃｅｒ　ｔｒｅａｔｍｅｎｔ' Ｎａｔ　Ｒｅｖ　Ｃａｎｃｅｒ Ｖｏｌ．４，　Ｎｏ．６, 2004, ｐ．４３７-４４７ *

Also Published As

Publication number Publication date
WO2007041546A3 (en) 2007-07-12
US20090136521A1 (en) 2009-05-28
EP1931769A2 (en) 2008-06-18
CA2624707A1 (en) 2007-04-12
WO2007041546A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
US20240335473A1 (en) Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (pgc1alpha) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (tils)
JP2009510165A (ja) 低酸素細胞を選択的に枯渇させるための方法
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
US20210113506A1 (en) Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
JP5476342B2 (ja) 光力学診断及び治療のためのローダミン誘導体
JP7574198B2 (ja) Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法
AU2010278738A1 (en) Antiangiogenic small molecules and methods of use
JP6764017B2 (ja) がんの処置での使用のためのコビシスタット
US20220387502A1 (en) Methods and composition for producing and using immune cells and stem cells for cell-based therapies
AU2021348477B2 (en) Csf1r kinase inhibitor and use thereof
US20060003020A1 (en) Anti-metastatic ability of mibefradil and gadolinium
US20240108721A1 (en) Dual targeting chimeric antigen receptors
CN114072158A (zh) 肺癌特异性骨髓浸润淋巴细胞及其用途
US20240358835A1 (en) Tumor infiltrating lymphocytes with increased metabolic activity
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
CN117980470A (zh) 治疗性nk细胞群
CN107206083A (zh) 改进的光动力学方法及由其获得的产物
US20150329824A1 (en) Z cells activated by zinc finger-like protein and uses thereof in cancer treatment
EP2956132A1 (en) Modulation of asymmetric proliferation
Alfar A NOVEL APPROACH TO SELECTIVELY TARGET AND REPROGRAM REGULATORY T CELLS IN THE TUMOR MICROENVIRONMENT
WO2025059644A1 (en) Metabolic immunomodulators that potentiate anti-tumor immunity in cancer
HK40069049A (en) Lung cancer specific marrow infiltrating lymphocytes and uses thereof
CN112516298A (zh) EpCAM-CAR-T和hsBCL9CT-24的组合物在制备抗肿瘤药物中的应用
HK40009323B (en) Methods and composition for producing and using immune cells and stem cells for cell-based therapies
HK40009323A (en) Methods and composition for producing and using immune cells and stem cells for cell-based therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121022